Objective: To compare the effect of a nutritional supplement used as a replacement meal in different pharmacological treatments on glycemia in patients with type 2 diabetes mellitus. Methods: Three groups of patients with diabetes were treated with pharmacological treatments: Group 1 Biguanide (08), Group 2 inhibitor of dipeptidyl peptidase-4 (07) and Group 3 Sulphonylurea/Biguanide (09). Glucerna® (Abbott Laboratories) supplementation was suggested to patients in the 3 groups. The initial glycemia in the three groups was: 206.13 ± 78.99 mg/dL; 276.14± 103.24 mg/dL and 310.89± 88.49 mg/dL for groups G1, G2 and G3 respectively. Regarding the glycemia evaluation, a basal and two post-treatments (control 1 and 2) were performed using the glucose oxidase-peroxidase method. Results: There was a significant decrease in glycemia in control 1 and 2 compared to baseline in patients with different pharmacological treatments and glycerine G1: 96.62± 58.88 mg/dL and 108.95± 78.25 mg/dL; G2: 147.97± 86.19 mg/dL and 153.86± 97.75 mg/dL; G3: 140.67± 37.42 mg/dL and 179.87± 70.71 mg/dL, however, when comparing the glycemia reduction of the controls in the three groups was not significant (p > 0.05). Conclusions: There is no significant difference in the decrease of glycemia in diabetic patients and in the use of nutritional supplement (Glucerna®) in different pharmacological treatments.
|Título traducido de la contribución||Effect of a nutritional supplement used in pharmacological treatments on glycaemia in diabetic patients type 2|
|Publicación||Revista Cubana de Farmacia|
|Estado||Publicada - 1 oct. 2017|
|Publicado de forma externa||Sí|
Nota bibliográficaPublisher Copyright:
© 2017 Revista Cubana de Farmacia. All rights reserved.
- Diabetes mellitus type 2
- Dipeptidyl peptidase-4